Healthcare Hedge Fund Calls Valeant Pricing “Outrageous” While Recommending Horizon
At this moment, there are significant investing opportunities in healthcare, Jim Flynn of Deerfield Partners said at the Invest for Kids Conference in Chicago Wednesday. Yet Valeant Pharmaceuticals is not one of them, he emphatically asserted as he outlined a potential relative value trade when he recommended a long investment in Horizon Pharmaceuticals.
Flynn: Valeant pushes financial structuring to its limit and pricing issues are more a statement on individual companies than pharma industry as a whole
Deerfield Partners is . . .
SORRY! This content is exclusively for paying members. If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.
|
